TY  - JOUR
A1  - Weller, Johannes
A1  - Schäfer, Niklas
A1  - Schaub, Christina
A1  - Potthoff, Anna-Laura
A1  - Steinbach, Joachim Peter
A1  - Schlegel, Uwe
A1  - Sabel, Michael
A1  - Hau, Peter
A1  - Seidel, Clemens
A1  - Krex, Dietmar
A1  - Goldbrunner, Roland
A1  - Pietsch, Torsten
A1  - Tzaridis, Theophilos-Dimitrios
A1  - Zeyen, Thomas
A1  - Borger, Valeri
A1  - Güresir, Erdem Özer
A1  - Vatter, Hartmut
A1  - Herrlinger, Ulrich
A1  - Schneider, Matthias
T1  - Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
T2  - Journal of neuro-oncology
N2  - Purpose: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy.
Methods: The impact of obesity (BMI ≥ 30 kg/m2) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables.
Results: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm.
Conclusion: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.
KW  - Glioblastoma
KW  - Temozolomide
KW  - Obesity
KW  - MGMT
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69458
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-694589
SN  - 1573-7373
N1  - The involved trials were supported by the German Ministry for Education and Science (CeTeG/NOA-09 [10]), Roche (GLARIUS [12]) and Bundesministerium für Bildung und Forschung (Grant No. 01KG1005). Open Access funding enabled and organized by Projekt DEAL.
VL  - 159
IS  - 1
SP  - 95
EP  - 101
PB  - Springer Science + Business Media B.V
CY  - Dordrecht [u.a.]
ER  -